Intravesical electrophoresis of doxorubicin for superficial bladder cancer. Results of prospective randomized trial

Abstract

The data of prospective randomized trial including comparative analysis of two treatment arm results are reported. The patients of group A underwent TUR with following intravesical electrophoresis of 50 mg of chemotherapeutic drug Doxorubicin whereas patients of group B were treated with TUR which followed by intravesical instillation of Doxorubicin. Each group included 17 patients with superficial bladder cancer. In group A complete remission were registered in 11 (64,7%), partial regression in 3 (17,6%) and stabilization in 3 (17,6%) patients. In group A complete remission were found in 6 (35,3%), partial regression in 2 (11,8%) and stabilization in 9 (52,9%) patients. Intravesical electrochemotherapy with Doxorubicin is more effective in comparison to standard intravesical chemotherapy with the same drug, which was expressed by higher rate of positive responses to treatment. The positive response rate were 82,4% in group A verse 47,1% in group B, 2-year survival rate was also better in group A (75% verse 51,9%).